scholarly journals Interferoncontaining drugs: clinical, pharmacological, and immunological points of their use for respiratory diseases treatment

2021 ◽  
pp. 210-220
Author(s):  
J. M. Salmasi ◽  
A. N. Kazimirskii ◽  
I. V. Kukes ◽  
G. V. Poryadin ◽  
D. I. Pozdnyakov
Keyword(s):  
Respiratory Diseases ◽  
Inflammatory Diseases ◽  
Experimental Studies ◽  
Mechanisms Of Action ◽  
Interferon Alfa ◽  
Immunomodulatory Drugs ◽  
Pediatric Practice ◽  
Innate And Adaptive Immunity ◽  
Immunomodulatory Drug ◽  
Area Of Application

Nowadays pharmacological group classified by the ATX L03AX code as immunostimulants is demand among doctors of various specialties. The main area of application of such drugs is infectious respiratory viral processes, which are associated not only with the pathogenetic action of viruses, but also with a high risk of bacterial complications. Thus, the practitioner is faced with the task of preventing such complications and choosing an immunomodulatory drug with the most pronounced pharmacodynamic properties in this regard. In Russia, there are many drugs belonging to the group of immunomodulators with different mechanisms of action and end pharmacological and immunological points of application. The emphasis of the mechanisms of action of such drugs is made on the effect on the systems of both innate and adaptive immunity. At the same time, the severity of the effect on both one and the other immune system in drugs that is strong enough may differ, which requires special attention from the doctor when choosing a drug in a particular situation. A special place in the group of immunomodulatory drugs used for infectious respiratory diseases is occupied by interferoncontaining drugs that contain interferon alfa-2b (IFN-a2b). In addition, there are combination of IFN-a2b with an immunoglobulin complex, which increases the effectiveness of this drug in the treatment of various infectious and inflammatory diseases. The article describes the theoretical and practical aspects of administration this combined drug in pediatric practice and presents own experimental studies.

scholarly journals Modulation of Autophagy for Controlling Immunity

Cells ◽  
2019 ◽  
Vol 8 (2) ◽  
pp. 138 ◽  
Author(s):  
Young Jin Jang ◽  
Jae Hwan Kim ◽  
Sanguine Byun
Keyword(s):  
Immune Responses ◽  
Therapeutic Potential ◽  
Inflammatory Diseases ◽  
Mechanisms Of Action ◽  
Innate And Adaptive Immunity ◽  
Pathological Conditions ◽  
Physiological Homeostasis ◽  
Autophagy Pathway ◽  
Key Steps ◽  
Additional Role

Autophagy is an essential process that maintains physiological homeostasis by promoting the transfer of cytoplasmic constituents to autophagolysosomes for degradation. In immune cells, the autophagy pathway plays an additional role in facilitating proper immunological functions. Specifically, the autophagy pathway can participate in controlling key steps in innate and adaptive immunity. Accordingly, alterations in autophagy have been linked to inflammatory diseases and defective immune responses against pathogens. In this review, we discuss the various roles of autophagy signaling in coordinating immune responses and how these activities are connected to pathological conditions. We highlight the therapeutic potential of autophagy modulators that can impact immune responses and the mechanisms of action responsible.

scholarly journals Possibilities of using multidirectional immunomodulators for acute and recurrent infectious and inflammatory diseases of the upper respiratory tract

2021 ◽  
pp. 89-95
Author(s):  
S. V. Morozova ◽  
L. V. Selezneva
Keyword(s):  
Immune System ◽  
Respiratory Tract ◽  
Respiratory Diseases ◽  
Inflammatory Diseases ◽  
Mechanisms Of Action ◽  
Biologically Active ◽  
Upper Respiratory Tract ◽  
Starting Point ◽  
Upper Respiratory

In many countries, with the prevention of acute respiratory diseases in children and adults, the use of various types of biologically active substances of natural and synthetic origin, called immunostimulants of various mechanisms of action, has been introduced. The purpose of this article is to provide a useful overview of main roles of available immunostimulants and their potential for use in inflammatory diseases of the upper respiratory tract. The article discusses aspects of the clinical use of immunomodulatory drugs in acute and recurrent infectious and inflammatory diseases of the respiratory tract (SARS-CoV-2 included). The mechanisms of action of immunomodulators on the immune system are briefly outlined. On the drug Imunorix the evidence base of mechanisms of correction of the immune system in respiratory diseases of the upper respiratory tract is given, as well as the analysis of the clinical efficacy of drug. The use of immunostimulator to increase the level of immunoglobulins (IgA, IgM, IgG) and subpopulations of T-lymphocytes (CD3 +, CD4 +). Also, the use of the drug has shown its usefulness in the appointment of antibacterial drugs in the treatment of upper respiratory tract infectious diseases. This article also provides an overview of recent clinical studies of drug. Researchers from various countries have tried to better clarify and define the mechanisms of action of immunostimulator both in vitro and in vivo. Of course, the improvement in research methodology over the past 20 years, and the acquired knowledge in various areas of clinical immunology, should become the starting point for further research on the drug. Randomized controlled trials of the trial use of the drug in the prevention of acute respiratory infections.

OCCURRENCE OF THE RISKS FOR DEVELOPMENT OF RESPIRATORY DISEASES IN CHILDREN EXPOSED TO THE CHEMICAL FACTORS OF THE EXPOSURE OF ALUMINA REFINERY- ASSOCIATED BUSINESS ACTIVITY

2019 ◽  
pp. 42-47 ◽  
Author(s):  
M.A. Zemlianova ◽  
I.V. Tikhonova
Keyword(s):  
Respiratory Tract ◽  
Respiratory Diseases ◽  
Inflammatory Diseases ◽  
Allergic Inflammation ◽  
Respiratory Morbidity ◽  
Upper Respiratory Tract ◽  
Negative Effects ◽  
Wide Range ◽  
Chemical Factors ◽  
Chronic Lymphoproliferative Diseases

Alumina refineries are among the leading sources of atmospheric air pollution with a wide range of pollutants hazardous to human respiratory organs. It is relevant to study and evaluate the occurrence of the risks for development of respiratory diseases in children living in the area affected by the emission components of an alumina refinery. We assessed air quality of the area under observation and comparison according to monitoring observations, risk of non-carcinogenic effects from the respiratory organs. The content of chemicals in the blood and urine adequate to risk factors was quantified. The structure of individual groups of respiratory diseases was analyzed. The causal relationships of violations of laboratory parameters with an increased content of chemicals in biological media were evaluated. It was found that an aerogenic exposure of chemical pollutants is formed on the territory with the production of metallurgical alumina. It determines the risk for development of respiratory diseases, exceeding an acceptable level up to 49.9 times. In the exposed children, the content of manganese, chromium, nickel, copper, xylenes, formaldehyde and aluminum, fluoride ion in the urine was increased to 4.2 times in relation to the indices in the comparison group. A high level of additional respiratory morbidity(1.8 times) was revealed. Chronic lymphoproliferative diseases of the nasopharynx and inflammatory diseases of the upper respiratory tract (up to 6.6 times more often), inflammatory diseases with a predominance of the mechanism of allergic inflammation ( up to 2.1 times more often)are more often detected in the framework of the respiratory diseases. Negative effects on the part of the respiratory system in the form of activation of antioxidant processes, the development of an inflammatory reaction, local, general and specific sensitization of the respiratory tract were established. It confirms the occurrence of the risks for the development of respiratory diseases in children in the exposure area of the chemical factors of alumina refinery-associated economic activity.

EFFECT OF KAGOCEL PREPARATION ON THE GENERATIVE FUNCTION OF EXPERIMENTAL ANIMALS AT ITS ADMINISTRATION IN THE INFANTILE PERIOD OF THEIR DEVELOPMENT

2017 ◽  
pp. 42-49
Author(s):  
T. A. Borovskaya ◽  
M. E. Poluektova ◽  
A. V. Vychuzhanina ◽  
V. A. Mashanova ◽  
Yu. A. Shchemerova
Keyword(s):  
Toxic Effect ◽  
Reproductive System ◽  
Safety Profile ◽  
Therapeutic Dose ◽  
Antiviral Drug ◽  
Experimental Studies ◽  
Reproductive Age ◽  
Pathological Changes ◽  
Pediatric Practice ◽  
Experimental Animals

In experimental studies on rats (males, females) at their infantile stage starting from 10 days, a potential delayed toxic effect of the antiviral drug Kagocel on the reproductive system was studied. The drug was administered for 12 days in a therapeutic dose and at a dose 10-fold higher than the therapeutic one. Reproductive safety was estimated after animals reached the reproductive age (2.5 months). It was found out that the drug, when administered in both doses, does not decrease the fertility of animals, does not induce morphological and pathological changes in the sex glands, and does not have toxic effect on the offspring. Obtained data characterize Kagocel as a preparation with a wide reproductive safety profile and show that it can be used in pediatric practice for infants.

The Role of Leukotrienes Inhibitors in the Management of Chronic Inflammatory Diseases

2020 ◽  
Vol 14 (1) ◽  
pp. 15-31
Author(s):  
Deepak Meshram ◽  
Khushbo Bhardwaj ◽  
Charulata Rathod ◽  
Gail B. Mahady ◽  
Kapil K. Soni
Keyword(s):  
Respiratory Diseases ◽  
Inflammatory Diseases ◽  
Leukotriene B4 ◽  
Published Data ◽  
Free Text ◽  
Plant Origin ◽  
Medical Subject Headings ◽  
Leukotriene Antagonists ◽  
Mesh Terms ◽  
Mediators Of Inflammation

Background: Leukotrienes are powerful mediators of inflammation and interact with specific receptors in target cell membrane to initiate an inflammatory response. Thus, Leukotrienes (LTs) are considered to be potent mediators of inflammatory diseases including allergic rhinitis, inflammatory bowel disease and asthma. Leukotriene B4 and the series of cysteinyl leukotrienes (C4, D4, and E4) are metabolites of arachidonic acid metabolism that cause inflammation. The cysteinyl LTs are known to increase vascular permeability, bronco-constriction and mucus secretion. Objectives: To review the published data for leukotriene inhibitors of plant origin and the recent patents for leukotriene inhibitors, as well as their role in the management of inflammatory diseases. Methods: Published data for leukotrienes antagonists of plant origin were searched from 1938 to 2019, without language restrictions using relevant keywords in both free text and Medical Subject Headings (MeSH terms) format. Literature and patent searches in the field of leukotriene inhibitors were carried out by using numerous scientific databases including Science Direct, PubMed, MEDLINE, Google Patents, US Patents, US Patent Applications, Abstract of Japan, German Patents, European Patents, WIPO and NAPRALERT. Finally, data from these information resources were analyzed and reported in the present study. Results: Currently, numerous anti-histaminic medicines are available including chloropheneremine, brompheniramine, cetirizine, and clementine. Furthermore, specific leukotriene antagonists from allopathic medicines are also available including zileuton, montelukast, pranlukast and zafirlukast and are considered effective and safe medicines as compared to the first generation medicines. The present study reports leukotrienes antagonistic agents of natural products and certain recent patents that could be an alternative medicine in the management of inflammation in respiratory diseases. Conclusion: The present study highlights recent updates on the pharmacology and patents on leukotriene antagonists in the management of inflammation respiratory diseases.

New opportunities of halotherapy in the prevention and medical rehabilitation of children

2021 ◽  
pp. 37-47
Author(s):  
Alina Vyacheslavovna Chervinskaya ◽  
Irena Vladimirovna Pogonchenkova ◽  
Maya Alekseevna Khan ◽  
Natalya Anatolievna Mikitchenko ◽  
Natalya Anatolievna Lyan
Keyword(s):  
Sodium Chloride ◽  
Bronchial Asthma ◽  
Respiratory Diseases ◽  
High Efficiency ◽  
Medical Rehabilitation ◽  
Favorable Effect ◽  
Group Method ◽  
Biophysical Properties ◽  
Pediatric Practice ◽  
Highly Dispersed

The article is devoted to new possibilities of using halotherapy in the prevention, treatment and medical rehabilitation of children. In recent years, active work has been carried out to develop new effective methods of reproducing the aerodispersed medium in the form of haloingalation therapy or by group method — in the conditions of a halochamber. The therapeutic effect of halotherapy is determined by the biophysical properties of a dry highly dispersed aerosol of sodium chloride. The paper presents the biophysical properties of the main active factor of halotherapy, i.e. a dry highly dispersed aerosol of sodium chloride, and reveals some aspects of the formation of the mechanism of therapeutic action. The anti-inflammatory, draining, mucolytic, immunomodulatory, sanogenetic effect of haloaerosol is shown. In pediatric practice, haloaerosol therapy is used for medical rehabilitation of children with respiratory diseases (bronchial asthma, bronchitis), ENT pathology (rhinosinusitis, tonsillitis, pharyngitis), skin diseases. Halotherapy is the method of choice in the prevention of acute respiratory diseases and improving the health of children in general education institutions. The high efficiency of the complex application of halotherapy in various diseases in children has been established. A promising direction for the development of halotherapy is the development of combined exposure technologies. The high efficiency of the use of haloingalation therapy in combination with magnetic therapy in the treatment of acute rhinosinusitis in children has been proven. Based on the conducted studies, a favorable effect of the use of halotherapy and flutter therapy on clinical and functional parameters in children with bronchial asthma was revealed. The data on the possibility of combined use of halotherapy with a pulsed low-frequency electrostatic field in the medical rehabilitation of children suffering from bronchial asthma are presented. Simplicity, safety, the possibility of personalization of exposure and good tolerability by children expands the possibilities for using halotherapy in pediatric practice.

scholarly journals Antibiotic-associated diarrhea in children: how to identify, what to do and how to treat?

2016 ◽  
Vol 1 (1) ◽  
pp. 78-89
Author(s):  
I. N. Zakharova ◽  
I. V. Berezhnaya ◽  
E. B. Mumladze
Keyword(s):  
High Risk ◽  
Antibiotic Therapy ◽  
Intestinal Microbiota ◽  
High Probability ◽  
Pseudomembranous Colitis ◽  
Inflammatory Diseases ◽  
Pediatric Practice ◽  
Antibiotic Associated Diarrhea ◽  
New Generation ◽  
Very High

Rational antibiotic therapy is one of the most important components in the treatment of children with various infectious and inflammatory diseases. However, wide and sometimes unjustified use of AB in pediatric practice often leads to the development of a variety of complications. Children receiveing AB, especially during the first 5 years of life, are at a very high risk of developing antibiotic-associated diarrhea (AAD) which manifests itself in three or more episodes of unformed stools for two or more consecutive days or for 8 weeks after withdrawal. The most relevant pathogen of AAD is C. difficile which, according to various data, causes from 10 to 25% of AAD cases and 90 to 100% of all cases of pseudomembranous colitis (PMC). Given the high probability of developing dangerous complications such as PMC, special attention should be paid to the prevention of the infection associated with C. difficile by reducing the frequency of uncontrolled and unjustified use of AB. A new generation of eco-antibiotics can be recommended which allow to maintain diversity of the intestinal microbiota and are less likely to cause complications.

scholarly journals Experience in treatment and prevention of respiratory diseases relapses in children with the use of the phytotherapeutic complex «Alpicol»: feedback of doctors in Ukraine

2021 ◽  
pp. 12-22
Author(s):  
О.К. Koloskova ◽  
◽  
A.L. Kosakovskyi ◽  
T.M. Bilous ◽  
I.B. Horbatiuk ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Therapeutic Efficacy ◽  
Respiratory Diseases ◽  
Conflicts Of Interest ◽  
Inflammatory Diseases ◽  
Clinical Manifestations ◽  
Herbal Medicines ◽  
Upper Respiratory Tract ◽  
Treatment And Prevention ◽  
Parents And Children

Infectious and inflammatory diseases of the respiratory tract in children are the «leaders» among all pathologies of childhood. Optimization of therapeutic and prophylactic approaches for infectious and inflammatory pathologies of the respiratory system by reducing the frequency of unreasonable antibiotic therapy and eliminating polypragmatic use is a relevant problem of modern pediatrics and otolaryngology. According to WHO guidelines, modern standardized herbal medicines are not inferior in efficiency to synthetic ones. The aim — to analyze the results of assessment by doctors of the preventive and therapeutic efficacy of the remedy «Alpicol» on the basis of a questionnaire, as well as clinical examination of patients before using the medication and after completion of the course of treatment. Materials and methods. The advantages of «Alpicol» were analyzed through a questionnaire offered by first contact practitioners to children in order to receive feedback on the assessment of the preventive and therapeutic efficacy of this medication. Doctors from 9 regions of Ukraine were involved, and 6,093 questionnaires of children of different ages were analyzed. Results. The frequency of registration of a pronounced paediatric pain (3 scores) with the use of the «Alpicol» medication significantly decreased (23.7 times), a moderate manifestation of the disease (2 scores), was 17 times less at the same time, mild manifestations of paediatric pain remained at the same level. Patients with a comorbid pathology of the respiratory tract in the form of recurrent lesions of the upper and lower airways during the 2nd visit received a zero score (no symptoms) significantly less frequently than children with pathology of the upper respiratory tract with 62.6% of cases versus 72.2% of observations, respectively (p<0.05). As a result of the use of the course of «Alpicol» medication, a statistically significant decrease in the severity of the catarrhal symptom complex was achieved, since the proportion of the course of disease, assessed by the maximum number of scores, decreased by 29.6 times, moderate (score 2) — 13.3 times, and zero scores appeared 5.7 times more often. At the same time, the proportion of patients with a mild course of catarrh practically did not change. Conclusions. «Alpicol» has a multi;vector efficacy against the complex of symptoms that accompany infectious and inflammatory exacerbations of recurrent respiratory diseases. This is manifested by a decrease in the severity of clinical manifestations of the disease, as well as in an increase in cases of clinical stabilization of the patient's condition, which demonstrates the therapeutic and prophylactic effect of the drug «Alpicol» on the course of recurrent respiratory diseases in children. The study was carried out in accordance with the principles of the Declaration of Helsinki. The study protocol was adopted by the Local Ethics Committee of all institutions indicated in this research. The informed consent of parents and children was obtained. The authors declare that they have no conflicts of interest. Key words: ecurrent respiratory diseases, treatment and prevention, children, phytocomplexes.

Sign in / Sign up

Export Citation Format

Share Document